Fig. 6
From: Anti-Aβ antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology
Effect of passive anti-Aβ immunization on human WT tau-induced pathological manifestations. a Representative images of human WT tau protein distribution (HT7, in red) in the ipsilateral side of the hippocampus, in a non-treated and a mAb11-treated 5xFAD/AAV-tau mouse. DAPI is shown in grey. Scale bars: 500 µm. b Percentage of the ipsi- and contralateral hippocampal region covered by the HT7 staining, showing the effects of the mAb11-treatment in either 5xFAD/AAV-tau or WT/AAV-tau mice. Note the significant decrease of HT7 immunoreactivity in the ipsilateral hippocampus of 5xFAD/AAV-tau mice. c Representative images of the HT7-positive dystrophic neurites (red puncta indicated by arrowheads) near Aβ deposits (4G8, in green) in the contralateral hippocampus of a control sham-treated and a mAb11-treated 5xFAD/AAV-tau mouse. DAPI is shown in blue. Scale bars: 25 µm. d Percentage of the Aβ-positive area (including a 5-µm wide rim as described in Fig. 4) covered by the HT7 signal, which typically labels dystrophic neurites in the contralateral hippocampus of 5xFAD/AAV-tau mice. Note the significant decrease of the surface covered by human tau positive dystrophic neurites in the mAb11-treated mice. e Percentage of the ipsilateral hippocampus covered with AT8 positive signal in control sham-treated 5xFAD/AAV-tau mice compared to mAb11-treated mice. f Percentage of the plaque area (5-µm extended Aβ plaque area as described in Fig. 4) covered by AT8 positive puncta in the contralateral hippocampus of sham-treated and mAb11-treated 5xFAD/AAV-tau mice. g Hippocampal degeneration assessed by the ipsi/contralateral ratio of the DG area in the sham-treated and mAb11-treated 5xFAD/AAV-tau mice. Statistical analyses: two-way ANOVA with post hoc Sidak’s multiple comparison test (b) and unpaired two-tailed Student’s t-test (d–g), *p < 0.05, ***p < 0.001; control sham-treated 5xFAD/AAV-tau: n = 14 mice (b, d) and n = 15 mice (e–g), mAb11-treated 5xFAD/AAV-tau: n = 16 mice, control sham-treated WT/AAV-tau: n = 14 mice, mAb11-treated WT/AAV-tau: n = 16 mice